PMID- 17179229
OWN - NLM
STAT- MEDLINE
DCOM- 20070531
LR  - 20231213
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 109
IP  - 7
DP  - 2007 Apr 1
TI  - Expression and release of soluble HLA-E is an immunoregulatory feature of 
      endothelial cell activation.
PG  - 2806-14
AB  - Human leukocyte antigen (HLA)-E belongs, with HLA-G and HLA-F, to the non-classic 
      major histocompatibility complex (MHC) class I (Ib) molecules, broadly defined by 
      a limited polymorphism and a restricted pattern of cellular expression. In 
      contrast to HLA-G, the expression and function of HLA-E and HLA-F in physiologic 
      and pathologic processes remain poorly established. In the present study, we show 
      that HLA-E protein expression in normal human nonlymphoid organs is mainly 
      restricted to endothelial cells (ECs). HLA-E is also basally expressed by B and T 
      lymphocytes, natural killer (NK) cells and by macrophages. We demonstrate that 
      tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), and 
      interferon gamma (IFNgamma) up-regulate the cell-surface expression of HLA-E on 
      ECs in vitro and induce the release of soluble HLA-E (sHLA-E). HLA-E 
      up-regulation protects IFN-gamma-activated ECs from NK-mediated cell lysis, while 
      sHLA-E protects bystander cells. Finally, sHLA-E is not detected in normal sera, 
      and increased serum levels correlate with disease activity in patients with 
      antineutrophil cytoplasmic antibody-associated systemic vasculitis. Thus, HLA-E 
      expression and release of sHLA-E are features of EC activation and emphasize 
      immunoregulatory functions of the endothelium. The present identification of 
      soluble HLA-E molecules may have important implications in understanding the 
      pathogenesis of immune-mediated vascular diseases and for the diagnosis and 
      monitoring of patients.
FAU - Coupel, Stephanie
AU  - Coupel S
AD  - Institut National de la Sante et de la Recherche Medicale, Unit 643, Institut de 
      Transplantation et de Recherche en Transplantation, Nantes, France.
FAU - Moreau, Anne
AU  - Moreau A
FAU - Hamidou, Mohamed
AU  - Hamidou M
FAU - Horejsi, Vaclav
AU  - Horejsi V
FAU - Soulillou, Jean-Paul
AU  - Soulillou JP
FAU - Charreau, Beatrice
AU  - Charreau B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Cytokines)
RN  - 0 (DNA Primers)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (KLRD1 protein, human)
RN  - 0 (NK Cell Lectin-Like Receptor Subfamily D)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Natural Killer Cell)
SB  - IM
MH  - Base Sequence
MH  - Cells, Cultured
MH  - Cytokines/pharmacology
MH  - Cytotoxicity, Immunologic
MH  - DNA Primers/genetics
MH  - Endothelial Cells/drug effects/*immunology
MH  - Female
MH  - Gene Expression
MH  - HLA Antigens/blood/genetics/*metabolism
MH  - Histocompatibility Antigens Class I/blood/genetics/*metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Killer Cells, Natural/immunology
MH  - Leukocytes/immunology
MH  - NK Cell Lectin-Like Receptor Subfamily D/metabolism
MH  - Pregnancy
MH  - Receptors, Immunologic/metabolism
MH  - Receptors, Natural Killer Cell
MH  - Solubility
MH  - Vasculitis/immunology
MH  - HLA-E Antigens
EDAT- 2006/12/21 09:00
MHDA- 2007/06/01 09:00
CRDT- 2006/12/21 09:00
PHST- 2006/12/21 09:00 [pubmed]
PHST- 2007/06/01 09:00 [medline]
PHST- 2006/12/21 09:00 [entrez]
AID - S0006-4971(20)41781-1 [pii]
AID - 10.1182/blood-2006-06-030213 [doi]
PST - ppublish
SO  - Blood. 2007 Apr 1;109(7):2806-14. doi: 10.1182/blood-2006-06-030213.